Potential Target for Uterorelaxant Drugs
Author Information
Author(s): Bardou Marc, Rouget Céline, Breuiller-Fouché Michèle, Loustalot Catherine, Naline Emmanuel, Sagot Paul, Frydman René, Morcillo Esteban J, Advenier Charles, Leroy Marie-Josèphe, Morrison John J
Primary Institution: Laboratoire de Physiologie et Pharmacologie Cardiovasculaires Expérimentales (LPPCE), Université de Bourgogne
Hypothesis
Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs?
Conclusion
ADRB3 agonists may be a promising option for managing preterm labor due to their effectiveness and resistance to desensitization.
Supporting Evidence
- ADRB3 is present and functional in human near-term myometrium.
- ADRB3 agonists can inhibit spontaneous contractions of myometrial strips.
- ADRB3 is predominant over ADRB2 in human myometrium.
- ADRB3 expression increases during pregnancy.
Takeaway
Scientists are looking at a new target called ADRB3 to help stop premature labor, which could be safer than current treatments.
Methodology
In-vitro studies were conducted to assess the effects of ADRB3 agonists on spontaneous contractions in human myometrial strips.
Limitations
The therapeutic efficiency of ADRB3 agonists remains to be established.
Participant Demographics
Human myometrial tissue samples from pregnant and non-pregnant women.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website